08u30 - 16u00
Mevr. Elisabetta Difilippo &
Mevr. Constanza Curotto,
Corning Life Sciences
€ 0,00 / persoon (excl BTW)
Annulaties dienen minstens 24 uur voor de aanvang van het event bij Elscolab gemeld te worden, telefonisch +32 (0)3 250 15 70 of per e-mail email@example.com. Indien er geen annulatie werd gemeld en er is een no-show, dan dienen wij de annulatiekosten van € 50/persoon (excl. BTW) door te rekenen.
Deze dag bestaat uit 4 technische seminars die je nieuwe inzichten, middelen en toepassingen voor onderzoek en ontwikkeling in biowetenschappen bieden. Je kan ervoor kiezen om 1 presentatie te volgen, een halve dag deel te nemen of zelfs de hele dag! Geef gewoon je keuze door via het inschrijvingsformulier.
08.30 - 09.00: Ontvangst.
09.00 - 10.15: 3D Cell Culture - Elisabetta Difilippo, Corning Life Sciences.
Advanced Models for 3D Cancer Applications.
10.15 - 10.45: Pauze.
10.45 - 12.00: 3D Cell Culture - Elisabetta Difilippo, Corning Life Sciences.
3D Cell Culture Technologies as Disease Models.
12.00 - 13.00: Lunch.
13.00 - 14.15: Cell & Gene Therapy - Constanza Curotto, Corning Life Sciences.
Scale-up Options for Stem Cell Therapy Manufacturing.
14.15 - 14.45: Pauze.
14.45 - 16.00: Cell & Gene Therapy - Constanza Curotto, Corning Life Sciences.
Advances in Immune Cell Therapy.
09.00 - 10.15: Advanced Models for 3D Cancer Applications.
In recent years, three-dimensional (3D) cell culture models have been emerging as the preferred in vitro cancer model as they better mimic the in vivo tumor microenvironment. For instance, 3D cultures develop hypoxic cores and demonstrate gradients of soluble factors and a diffusion profile for drugs similar to solid tumors. Understanding the interactions between cancer cells and other cell types in the tumor microenvironment is also critical to predicting therapeutic efficacy. This seminar will discuss the following topics:
- An introduction to 3D cell culture
- Assay techniques in spheroid microplates
- Several 3D cancer models and technology tools used to better capture the complexity of the tumor microenvironment in assay-compatible formats.
10.45 - 12.00: 3D Cell Culture Technologies as Disease Models.
When it comes to mimicking human disease, traditional 2D cell culture and animal models are often inadequate and limited in their physiological relevance. Cells grown in 3D more closely mimic in vivo behavior in tissues and organs. There have been several recently established disease models involving human induced pluripotent stem cell (hiPSC)-derived 3D organoid culture systems. These systems also enable the use of patient-derived cells to generate models that provide valuable insight into the mechanism and progression of many diseases. The permeable support system can also be used to study disease pathophysiology and is particularly well suited for growing organotypic models at the air-liquid-interface (ALI). This seminar will discuss the following topics:
- Benefits of 3D versus traditional cell culture technologies as disease models
- Use of hiPSC-derived 3D organoid and/or permeable support culture systems to create disease-specific tissue/organ models e.g. brain, liver, pancreas, intestinal, lung, skin, retina
13.00 - 14.15: Scale-up Options for Stem Cell Therapy Manufacturing.
The global cell therapy market is expected to accelerate over the next few years driven by increasing advances in stem cell research and demand for cell therapy procedures. Corning is committed to helping orchestrate groundbreaking discoveries in the stem cell field, from fundamental upstream research to cell therapy manufacturing. Whether human pluripotent stem cell (hPSC) or adult stem cell-related (e.g. MSC), Corning provides advanced cell culture surfaces to transition to more chemically defined culture systems, vessels, media, and closed systems to ensure cell viability, reproducibility, and regulatory compliance. In this seminar, learn about:
- Different types of stem cells and therapies
- The stem cell therapy workflow from cell isolation to fill and finish and cryopreservation
- Corning’s portfolio of products for stem cell culture, differentiation and scale-up towards GMP manufacturing including the use of stackable vessels and microcarrier technologies
14.45 - 16.00: Advances in Immune Cell Therapy.
Immune cell therapy is one of the most exciting and fastest growing sectors in the translational and regenerative medicine industry. The immunotherapy space is attracting significant interest and investment, particularly in the onco-immunology segment with the recent historic approval of 2 chimeric antigen receptor (CAR)-T therapies. Such therapies promise new treatment for cancer patients and the remarkable success has accelerated research into CAR-T and other clinically-relevant immune cell types and a global landscape of clinical trials. In this seminar, learn about:
- Different types of immune cell therapies and recent CAR-T progress
- The immune cell therapy workflow from cell isolation to virus packaging, cell activation and expansion, harvesting and cryopreservation
- Corning’s portfolio of products including specialized lymphocyte serum-free media, reagents, culture flasks and bags and cryopreservation products